<?xml version='1.0' encoding='UTF-8'?>
<chapter id="ch0014">
    <title>AUTHOR AND EDITOR CONFLICTS OF INTEREST</title>
    <sect1 id="ch0014s0001">
      <title>AUTHOR AND EDITOR CONFLICTS OF INTEREST</title>
      <anchor id="ch0014s010000a0001"/>
      <anchor id="ch0014s000000a0001"/>
      <para id="ch0014s000000p0001"><emphasis role="strong">Maiken Calving Arendruo</emphasis> (coauthor on <ulink url="ch0157#ch0157s0001">chapter 135</ulink>) received research grants/contract work (monies paid to the Statens Serum Institut) from Amplyx, Basilea, Cidara, F2G, Gilead, Novabiotics, Scynexis, and T2 Biosystems and speaker honoraria (personal fee) from Astellas, Gilead, Novartis, MSD, and Seges. Dr. Calving-Arendrup is the current chairman of the EUCAST antifungal susceptibility testing subcommittee.</para>
      <para id="ch0014s000000p0002"><emphasis role="strong">N. Esther Babady</emphasis> (Section Editor; coauthor on <ulink url="ch0103#ch0103s0001">chapters 84</ulink> and <ulink url="ch0108#ch0108s0001">89</ulink>) receives research grants from GenMark Diagnostics, Copan Diagnostics, and Seres Therapeutics. Dr. Babady serves on the Scientific Advisory Committees for Agen Biosciences and Bio-Rad and on the Clinical Advisory Committee for Arc Bio Inc.</para>
      <para id="ch0014s000000p0003"><emphasis role="strong">Matthew J. Binnicker</emphasis> (Section Editor; coauthor on <ulink url="ch0102#ch0102s0001">chapters 83</ulink> and <ulink url="ch0103#ch0103s0001">84</ulink>) is an advisory board member for Luimnex/DiaSorin molecular and Mammoth Biosciences and receives speaking honoraria from Quidel, Abbott, Roche and Seegene.</para>
      <para id="ch0014s000000p0004"><emphasis role="strong">Richard S. Bradbury</emphasis> (coauthor on <ulink url="ch0170#ch0170s0001">chapters 147</ulink> and <ulink url="ch0178#ch0178s0001">154</ulink>) is a coauthor on the following patent (assigned to the Centers for Disease Control and Prevention): Eldin Talundzic, Richard S. Bradbury, Christian Olsen, Briana Flaherty. World Intellectual Property Organization (WIPO) Patent WO2019060840. Removing Interfering Host Nucleic Acids for Molecular Parasite Detection; granted 28 March 2019.</para>
      <para id="ch0014s000000p0005"><emphasis role="strong">Patricia A. Bradford</emphasis> (coauthor on <ulink url="ch0090#ch0090s0001">chapter 72</ulink>) is an independent microbiology consultant whose clients include Acrum, Allecra, Boston Pharma, Botanix, Bugworks, CarbX, Cipla, Debiopharm, Entasis, Fedora, Sinovent, Vivli, Zai Labs and owns stock in Pfizer. MC is an employee of JMI Laboratories which was contracted to perform services in 2020 for Affinity Biosensors, Allergan, Amicrobe, Inc., Amplyx Pharma, Artugen Therapeutics USA, Inc., Astellas, Basilea, Beth Israel Deaconess Medical Center, BIDMC, BioMérieux., Inc., BioVersys Ag, Bugworks, Cidara, Cipla, Contrafect, Cormedix, Crestone, Inc., Curza, CXC7, Entasis, Fedora Pharmaceutical, Fimbrion Therapeutics, Fox Chase, GlaxoSmithKline, Guardian Therapeutics, Hardy Diagnostics, IHMA, Janssen Research &amp; Development, Johnson &amp; Johnson, Kaleido Biosciences, KBP Biosciences, Luminex, Matrivax, Mayo Clinic, Medpace, Meiji Seika Pharma Co., Ltd., Melinta, Menarini, Merck, Meridian Bioscience Inc., Micromyx, MicuRx, N8 Medical, Nabriva, National Institutes of Health, National University of Singapore, North Bristol NHS Trust, Novome Biotechnologies, Paratek, Pfizer, Prokaryotics Inc., QPEX Biopharma, Rhode Island Hospital, RIHML, Roche, Roivant, Salvat, Scynexis, SeLux Diagnostics, Shionogi, Specific Diagnostics, Spero, SuperTrans Medical LT, T2 Biosystems, The University of Queensland, Thermo Fisher Scientific, Tufts Medical Center, Universite de Sherbrooke, University of Iowa, University of Iowa Hospitals and Clinics, University of Wisconsin, UNT System College of Pharmacy, URMC, UT Southwestern, VenatoRx, Viosera Therapeutics, and Wayne State University.</para>
      <para id="ch0014s000000p0006"><emphasis role="strong">Sharon C.A. Chen</emphasis> (coauthor on <ulink url="ch0144#ch0144s0001">chapter 123</ulink>) has received educational grants from F2G Ltd. and MSD Australia.</para>
      <para id="ch0014s000000p0007"><emphasis role="strong">Marc R. Couturier</emphasis> (Section Editor; author on <ulink url="ch0077#ch0077s0001">chapter 60</ulink>; coauthor on <ulink url="ch0167#ch0167s0001">chapter 144</ulink>) receives household income from BioMérieux. and owns stock in BioMérieux. Dr. Couturier also serves on the advisory board for Seegene and is a consultant for BioMérieux.</para>
      <para id="ch0014s000000p0008"><emphasis role="strong">Christopher D. Doern</emphasis> (coauthor on <ulink url="ch0022#ch0022s0001">chapter 7</ulink>) is on the Scientific Advisory Board for Quidel.</para>
      <para id="ch0014s000000p0009"><emphasis role="strong">Alexander L. Greninger</emphasis> (coauthor on <ulink url="ch0120#ch0120s0001">chapters 101</ulink>, <ulink url="ch0121#ch0121s0001">102</ulink>, and <ulink url="ch0124#ch0124s0001">105</ulink>) reports contract testing from Abbott, Cepheid, Novavax, Pfizer, Janssen and Hologic and research support from Gilead and Merck.</para>
      <para id="ch0014s000000p0010"><emphasis role="strong">Amanda T. Harrington</emphasis> (coauthor on <ulink url="ch0020#ch0020s0001">chapter 5</ulink>) receives grant funding and honoraria for presentations from BioFire Diagnostics.</para>
      <para id="ch0014s000000p0011"><emphasis role="strong">Albert Heim</emphasis> (coauthor on <ulink url="ch0126#ch0126s0001">chapter 107</ulink>) receives an honorarium for workshops and seminars presented by Hologeic Inc.</para>
      <para id="ch0014s000000p0012"><emphasis role="strong">Hans H. Hirsch</emphasis> (coauthor on <ulink url="ch0128#ch0128s0001">chapter 109</ulink>) serves as a consultant for Molecular Probes, Roches Diagnostics, and Vera Therapeutics and is a biotest speakers for Gilead.</para>
      <para id="ch0014s000000p0013"><emphasis role="strong">Nathan A. Ledeboer</emphasis> (Section Editor; coauthor on <ulink url="ch0054#ch0054s0001">chapters 37</ulink>, <ulink url="ch0055#ch0055s0001">38</ulink>, and <ulink url="ch0056#ch0056s0001">39</ulink>) serves as a consultant/Scientific Advisory Board member for Shionogi, Affinity Biosciences/Life Scale Technologies, Cytovale, ThermoFisher Scientific, Luminex, GeneCapture, Inflammatix, Copan Diagnostics, Lucira, 3iDx, and Specific Technologies/BioMérieux. Dr. Ledeboer is also a board member for CosmosID.</para>
      <anchor id="ch0014s000000a0002"/>
      <beginpage/>
      <para id="ch0014s000000p0014"><emphasis role="strong">James S. Lewis</emphasis> (coauthor on <ulink url="ch0089#ch0089s0001">chapter 71</ulink>) is a consultant for Merck, Cidara, and Selux Diagnostics.</para>
      <para id="ch0014s000000p0015"><emphasis role="strong">Blaine A. Mathison</emphasis> (coauthor on <ulink url="ch0159#ch0159s0001s0001">chapters 136</ulink> and <ulink url="ch0167#ch0167s0001">144</ulink>; author on <ulink url="ch0175#ch0175s0001">chapter 152</ulink>) has received research reagents from Apacor and Techcye.</para>
      <para id="ch0014s000000p0016"><emphasis role="strong">Erin McElvania</emphasis> (coauthor on <ulink url="ch0022#ch0022s0001">chapter 7</ulink>) is a speaker for BD Scientific.</para>
      <para id="ch0014s000000p0017"><emphasis role="strong">Robin Patel</emphasis> (Volume Editor) reports grants from ContraFect, TenNor Therapeutics Limited, and BioFire. Dr. Patel is a consultant to PhAST, Torus Biosystems, Day Zero Diagnostics, Mammoth Biosciences, and HealthTrackRx; monies are paid to Mayo Clinic. Mayo Clinic and Dr. Patel have a relationship with Pathogenomix. Dr. Patel has research supported by Adaptive Phage Therapeutics. Mayo Clinic has a royalty-bearing know-how agreement and equity in Adaptive Phage Therapeutics. Dr. Patel is also a consultant to Netflix, Abbott Laboratories, and CARB-X. In addition, Dr. Patel has a patent on Bordetella pertussis/parapertussis PCR issued, a patent on a device/method for sonication with royalties paid by Samsung to Mayo Clinic, and a patent on an anti-biofilm substance issued. Dr. Patel receives honoraria from the NBME, Up-to-Date and the Infectious Diseases Board Review Course.</para>
      <para id="ch0014s000000p0018"><emphasis role="strong">Jean B. Patel</emphasis> (Section Editor, coauthor on <ulink url="ch0093#ch0093s0001">chapter 75</ulink>) is an employee of Beckman Coulter Diagnostics and is a shareholder of Danaher stock.</para>
      <para id="ch0014s000000p0019"><emphasis role="strong">Benjamin A. Pinsky</emphasis> (Section Editor, author on <ulink url="ch0136#ch0136s0001">chapter 116</ulink>; coauthor on <ulink url="ch0101#ch0101s0001">chapters 82</ulink>, <ulink url="ch0103#ch0103s0001">84</ulink>, and <ulink url="ch0112#ch0112s0001">93</ulink>) has received research funding from Abbott, Agilent, Altona Diagnostics, Gentegra, Hologic, Kryptos Biotechnologies, Pathogen Dx, and Vela Diagnostics. MesoScale Discovery has provided reagents and instruments. He receives royalties from Globavir and BioRad.</para>
      <para id="ch0014s000000p0020"><emphasis role="strong">Bobbi S. Pritt</emphasis> (Volume Editor; <ulink url="ch0163#ch0163s0001s0001">chapter 140</ulink>; coauthor <ulink url="ch0085#ch0085s0001">chapter 68</ulink>) serves on the Board of Governors for the College of American Pathologists (CAP) and receives royalties from the CAP Press.</para>
      <para id="ch0014s000000p0021"><emphasis role="strong">Justin D. Radolf</emphasis> (coauthor on <ulink url="ch0080#ch0080s0001">chapter 63</ulink>) has received royalties for recombinant T. Pallidum proteins used for serological diagnostics.</para>
      <para id="ch0014s000000p0022"><emphasis role="strong">Sandra S. Richer</emphasis> (coauthor on <ulink url="ch0093#ch0093s0001">chapter 75</ulink>) is an employee of BioMérieux.</para>
      <para id="ch0014s000000p0023"><emphasis role="strong">Robert W. Shafer</emphasis> (coauthor on <ulink url="ch0135#ch0135s0001">chapter 115</ulink>) has served on advisory boards for Gilead Sciences and GlaxoSmithKline.</para>
      <para id="ch0014s000000p0024"><emphasis role="strong">Patricia J. Simner</emphasis> (Section Editor; coauthor on <ulink url="ch0094#ch0094s0001">chapter 76</ulink>) reports research contracts from BD Diagnostics, OpGen Inc., Affinity Biosensors, Qiagen Sciences Inc., and T2 Diagnostics. Dr. Simner serves on the speaker’s bureau for GenMark X, BD Diagnostics, and OpGen Inc. In addition, Dr. Simner has research collaborations with Ares Genetics, CosmosID, IDbyDNA, and Illumina and consults for OpGen Inc., BD Diagnostics, Shionogi Inc., Gene Capture, Qiagen Sciences, and Entasis.</para>
      <para id="ch0014s000000p0025"><emphasis role="strong">Neeraj K. Surana</emphasis> (coauthor on <ulink url="ch0032#ch0032s0001">chapter 17</ulink>) holds stock in Pfizer and serves as a consultant to MaaT Pharma.</para>
      <para id="ch0014s000000p0026"><emphasis role="strong">Eldin Talundzic</emphasis> (coauthor on <ulink url="ch0178#ch0178s0001">chapter 154</ulink>) is a coauthor on the following patent (assigned to the Centers for Disease Control and Prevention): Eldin Talundzic, Richard S Bradbury, Christian Olsen, Briana Flaherty. World Intellectual Property Organization (WIPO) Patent WO2019060840. Removing Interfering Host Nucleic Acids for Molecular Parasite Detection; granted 28 March 2019.</para>
      <para id="ch0014s000000p0027"><emphasis role="strong">Yi-Wei Tang</emphasis> (Section Editor; coauthor on <ulink url="ch0103#ch0103s0001">chapters 84</ulink> and <ulink url="ch0131#ch0131s0001">112</ulink>) is an employee of Danaher/Cepheid.</para>
      <para id="ch0014s000000p0028"><emphasis role="strong">Shawn Vasoo</emphasis> (coauthor on <ulink url="ch0018#ch0018s0001">chapter 3</ulink>) has received research support in-kind from BioMérieux (BioFire) and Rosco Diagnostica.</para>
      <para id="ch0014s000000p0029"><emphasis role="strong">Nathan P. Wiederhold</emphasis> (coauthor on <ulink url="ch0138#ch0138s0001s0001">chapters 117</ulink> and <ulink url="ch0145#ch0145s0001">124</ulink>) has received research support (monies paid to the University of Texas Health Science Center at San Antonio) from Astellas, Cepheid, Covance, F2G, and Sfunga, and has served on an advisory board for Mayne Pharma.</para>
      <para id="ch0014s000000p0030"><emphasis role="strong">Sean X. Zhang</emphasis> (Section Editor; coauthor on <ulink url="ch0145#ch0145s0001">chapter 124</ulink>) has received industry research funds and consultation fees from T2 Biosystems, KARIUS, Applied BioCode, Pearl Diagnostics, IMMY Diagnostics, Scanogen Inc., and Vela Diagnostics.</para>
      <para id="ch0014s000000p0031"><emphasis role="strong">Barbara A. Zimmer</emphasis> (coauthor on <ulink url="ch0091#ch0091s0001">chapter 73</ulink>) is an employee of Beckman Coulter Microbiology.</para>
    </sect1>
  </chapter>
